Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over ...